Download PDF
Endoscopy 2017; 49(10): 977-982
DOI: 10.1055/s-0043-113559
Innovations and brief communications
© Georg Thieme Verlag KG Stuttgart · New York

A new intraductal radiofrequency ablation device for inoperable biliopancreatic tumors complicated by obstructive jaundice: the IGNITE-1 study

Wim Laleman
1   Department of Gastroenterology & Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
,
Schalk van der Merwe
1   Department of Gastroenterology & Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
,
Len Verbeke
1   Department of Gastroenterology & Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
,
Dirk Vanbeckevoort
2   Department of Radiology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
,
Raymond Aerts
3   Department of Abdominal Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium
,
Hans Prenen
1   Department of Gastroenterology & Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
,
Eric Van Cutsem
1   Department of Gastroenterology & Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
,
Chris Verslype
1   Department of Gastroenterology & Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
› Author Affiliations
Further Information

Publication History

submitted 17 January 2017

accepted after revision 09 May 2017

Publication Date:
21 July 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Background and study aims Biliary stenting of unresectable malignant bile duct obstruction is generally accepted as the standard of care but it can be hampered by tumor ingrowth and stent dysfunction. We aimed to test the feasibility, safety, and biliary patency rate of a new endoscopically applied intraductal radiofrequency ablation (RFA) device.

Patients and methods Eighteen patients with inoperable malignant biliary obstruction underwent endoscopic retrograde cholangiopancreatography (ERCP)-directed RFA and stenting.

Results Between December 2014 and November 2015, 18 patients underwent RFA to the intended region, with no complications within 3 months of the procedure. Bilirubin levels post-RFA and stenting decreased significantly (7.8 ± 1 mg/dL to 1.7 ± 0.4 mg/dL; P < 0.001). At 90 and 180 days post-intervention, biliary patency was maintained in 80 % and 69 % of patients still alive at that time, respectively. The median overall stent patency was 110 days (range 16 – 374), with a median patient survival of 227 days (range 16 – 374).

Conclusion Intraductal RFA using a new device in patients with inoperable biliopancreatic cancer complicated by jaundice appeared feasible and safe with acceptable biliary patency. Randomized trials with prolonged follow-up are warranted.

ClinTrials.gov: NCT02468076.

 

  • References

  • 1 de Groen PC, Gores G, LaRusso NF. et al. Biliary tract cancers. NEJM 1999; 341: 1368-1378
    CrossrefPubMedGoogle Scholar
  • 2 Abraham NS, Barkun JS, Barkun AN. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc 2002; 56: 835-841
    CrossrefPubMedGoogle Scholar
  • 3 Vienne A, Hobeika E, Gouya H. et al. Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment. Gastrointest Endosc 2010; 72: 728-735
    CrossrefPubMedGoogle Scholar
  • 4 Strand DS, Cosgrove ND, Patrie JT. et al. ERCP-directed radiofrequency ablation and photodynamic therapy are associated with comparable survival in the treatment of unresectable cholangiocarcinoma. Gastrointest Endosc 2014; 80: 794-803
    CrossrefPubMedGoogle Scholar
  • 5 Steel AW, Postgate AJ, Khorsandi S. et al. Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction. Gastrointest Endosc 2011; 73: 149-153
    CrossrefPubMedGoogle Scholar
  • 6 Dolak W, Schreiber F, Schwaighofer H. et al. Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications. Surg Endosc 2014; 28: 854-860
    CrossrefPubMedGoogle Scholar
  • 7 Sharaiha RZ, Natov N, Glockenberg KS. et al. Comparison of metal stenting with radiofrequency ablation versus stenting alone for treating malignant biliary strictures: is there an added benefit?. Dig Dis Sci 2014; 59: 3099-3102
    CrossrefPubMedGoogle Scholar
  • 8 Tal AO, Vermehren J, Friedrich-Rust M. et al. Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction. World J Gastrointest Endosc 2014; 6: 13-19
    CrossrefPubMedGoogle Scholar
  • 9 Kallis Y, Phillips N, Steel A. et al. Analysis of endoscopic radiofrequency ablation of biliary malignant strictures in pancreatic cancer suggests potential survival benefit. Dig Dis Sci 2015; 60: 3449-3455
    CrossrefPubMedGoogle Scholar
  • 10 Laquière A, Boustière C, Leblanc S. et al. Safety and feasibility of endoscopic biliary radiofrequency ablation treatment of extrahepatic cholangiocarcinoma. Surg Endosc 2016; 30: 1242-1248
    CrossrefPubMedGoogle Scholar
  • 11 Alis H, Sengoz C, Gonenc M. et al. Endobiliary radiofrequency ablation for malignant biliary obstruction. Hepatobiliary Pancreat Dis Int 2013; 12: 423-427
    CrossrefPubMedGoogle Scholar
  • 12 Walter D, van Boeckel PG, Groenen MJ. et al. Cost efficacy of metal stents for palliation of extrahepatic bile duct obstruction in a randomized controlled trial. Gastroenterology 2015; 149: 130-138
    CrossrefPubMedGoogle Scholar
  • 13 Dumonceau JM, Tringali A, Blero D. et al. Biliary stenting: indications, choice of stents and results: European Society of Gastrointestinal Endoscopy clinical guideline. Endoscopy 2012; 44: 277-298
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Barret M, Leblanc S, Vienne A. et al. Optimization of the generator settings for endobiliary radiofrequency ablation. World J Gastrointest Endosc 2015; 10: 1222-1229
    PubMedGoogle Scholar